CD274 and neoplasm: Treatment of tumours with CD20-targeted AcTaferon (coupled hIFNa2-Q124R9 to PD-L1 Ab targeting mCD20) significantly shrunk tumour growth compared to anti-PD-L1 Ab treatment alone (P < 0.0001). Accordingly, combinational treatment may convert nonresponding tumours into responders.